This diagram represents the relative location of several key EREs within and around the human SIAH2 gene that were tested via CATCH in part B. (B) The DNA gel image shows that when specifically capturing the ERE B locus within the intron of SIAH2, incomplete DNA sonication allows capture of a locus approximately 1.1 kb away (ERE A ). In addition, lack of CH 2 O fixation results in capture of only the targeted fragment. However, with complete sonication and fixation, the ERE downstream of SIAH2 is also captured with the ERE B (DNSTRM). (C) This is a DNA gel image showing representative genomic DNA fragment size after complete sonication, using both unfixed (native) and fixed (1% CH 2 O) MCF-7 cells.
Supplementary Figure 7:
SIAH2 (vehicle-treated) enhancer CATCH-seq interaction peaks significantly overlap with enhancer marks (green) and ER-binding sites (gray) compared to statistically random control (red); the frequency of these overlaps increase with peak height. The same pattern is observed with estradiol treatment in Figure 4E .
Supplementary Figure 8: (A)
Graph detailing the number of SEEK genes 'predicted' by the vehicle-treated (gray) or estradiol-treated versions of SIAH2 enhancer CATCH-seq genome-wide. Genes predicted by both conditions (the majority) are in orange. (B) IPA showing the topmost statistically significant and enriched pathway for each small gene subset identified by CATCH-seq / SEEK overlap: female genital tract cancer (estradiol treated; blue) and endometrial cancer (vehicle treated; gray).
Supplementary Figure 9:
Analysis of CTCF binding adjacency/overlap with CATCH peaks. Numbers 1 and 2 denote replicates for GRB7 and EIF4A1. (A, left) Control GRB7 promoter region CATCH-seq interaction peaks do not significantly overlap with CTCF-binding sites (orange) and have very modest overlap with ER-binding sites (blue) compared to statistically random control (red); the frequency of these overlaps does not increase with peak height. (A, right) EIF4A1 promoter region CATCH-seq interaction peaks do not significantly overlap with CTCF-binding sites (orange), but have significant overlap with ER-binding sites (blue) compared to statistically random control (red); the frequency of the latter overlaps increases as a function of peak height. (B) SIAH2 downstream enhancer region CATCH-seq interaction peaks do not significantly overlap with CTCF-binding sites (orange), but have significant overlap with ER-binding sites (blue) compared to statistically random control (red); the frequency of the latter overlaps increases as a function of peak height. (C) MYC downstream enhancer region CATCH-seq interaction peaks show modest overlap with CTCF-binding sites (orange), but have significant overlap with ER-binding sites (blue) compared to statistically random control (red); the frequency of both overlaps increases, to some degree, as a function of peak height. The graphs depict, using a constant SEEK list of the top 100, 150, 200, or 300 identified genes, the continuous p-value of each CATCH experiment as the number of CATCH genes identified (used) in the analysis decreases. The vertical dotted red lines indicate the average point (of all CATCH experiments on the graph) at which CATCH results become non-significant (p=0.01). As CATCH is used to identify more gene promoters, it's ability to predict transcriptionally co-expressed genes (as measured by SEEK) increases. The negative log 10 of the p value was plotted on the y-axis against the number of CATCH genes used on the x-axis. The continuous p value was graphed for every CATCH experiment at varying steady-state SEEK depths of 100 (A), 150 (B), 200 (C) and 300 (D). The p-value here, is the effective point at which CATCH results can no longer, with p degree of certainty, be sure that a given identified gene is reliably co-expressed. Table contains the lists of genes that had both significant CATCH-seq signal peaks within 2kb of their promoters, and were also identified by SEEK as being transcriptionally co-expressed with one another. NB: SIAH2 is independently identified (w/ estradiol treatment). 
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